3 Pharma Stocks at Risk for Downgrades

AGIO, ABMD, and SRPT stocks may be ripe for a bearish trade

Oct 2, 2019 at 12:00 PM
facebook X logo linkedin


Drug stocks have underperformed recently, with just 19% of the 130 stocks we track under the "Pharmaceuticals & Biotechnology" umbrella trading north of their 80-day moving average. Analysts have barely budged in their bullish outlooks, though, with 65% of those covering these stocks still maintaining a "buy" rating -- putting the sector at risk for downgrades, which could create bigger headwinds.

Three names in particular that popped up on Schaeffer's Senior Quantitative Analyst Rocky White's list of stocks at risk for downgrades are artificial heart maker Abiomed, Inc. (NASDAQ:ABMD), cancer specialist Agios Pharmaceuticals Inc (NASDAQ:AGIO), and gene therapy name Sarepta Therapeutics Inc (NASDAQ:SRPT). This trio of stocks is currently sporting sharp year-to-date deficits alongside a majority of analyst "buy" ratings.

More specifically, Abiomed stock has shed 48% year-to-date -- bottoming at a two-year low of $163.40 earlier, and last seen down 1.1% at $168.33. Nevertheless, six of nine brokerages call the shares a "buy," or better, while the average 12-month price target of $256.43 is a nearly 53% premium to current trading levels. Bear notes could send ABMD shares to new lows.

abmd stock daily price chart on oct 2

Agios Pharmaceuticals, meanwhile, is down 1.8% at $32.97, bringing its 2019 loss to 28%. The shares have recovered slightly from their Sept. 30 five-year low at $31.46, but are still stuck beneath their 10-day moving average. There's room for more analysts to follow in the footsteps of RBC, which cut its AGIO price target yesterday, considering the consensus 12-month price target sits all the way up at $72. Plus, nearly 86% of covering analysts still say the stock's a "strong buy."

agio stock daily price chart on oct 2

Sarepta Therapeutics has surrendered more than 30% so far this year, down 1.4% today at $75.46. The stock's recent rally attempt off its Sept. 26 17-month was quickly halted by its 10-day moving average, and more downside could be ahead should analysts revise their upbeat ratings. Currently, 15 of 16 brokerages say SRPT stock is a "buy" or better, and the average 12-month target price of $190.76 is perched well above the equity's June 2018 record high of $176.50.

srpt stock daily price chart on oct 2

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI